VR Logo

Aerie Pharmaceuticals Inc. (AERI) download report


Healthcare | Drugs & Pharma

Aerie Pharmaceuticals Inc. (AERI) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.

IPO Date: 25-Oct-2013

CEO, Principal Financial Officer & Director: Mr. Raj Kannan

Co-Founder, Chief Innovation Officer & Head of Research and External Innovation: Dr. Casey C. Kopczynski Ph.D.

Listing: NASDAQ: AERI

Country: United States

Headquarters: Durham, NC

Website: https://www.aeriepharma.com

Key Facts

Market cap: $380.72 Mln

Revenue (TTM): $201.00 Mln

Earnings (TTM): $-68.74 Mln

Cash: $195.25 Mln

Total Debt: $337.18 Mln

Insider's Holding: 1.84%

Liquidity: Low

52 Week range: $4.81 - 17.21

Shares outstanding: 48,623,000

10 Years Aggregate:

  • CFO: $-760.79 Mln
  • EBITDA: $-920.11 Mln
  • Net Profit: $-1,102.85 Mln

Stock Performance

Time Period Aerie Pharmaceuticals (AERI) S&P BSE Healthcare S&P Small-Cap 600
YTD11.40-17.55-19.87
1 month44.28-3.85-10.07
3 months-20.20-11.97-17.25
1 Year-51.82-15.43-18.01
3 Years-35.8018.795.62
5 Years-31.949.095.60
10 Years--12.129.69
As on 30-Jun-2022
Year Aerie Pharmaceuticals (AERI) S&P Small-Cap 600 S&P BSE Healthcare
2021-48.0425.2720.87
2020-44.109.5761.45
2019-33.0520.86-3.55
2018-39.42-9.70-5.89
201757.8611.730.49
201655.4424.74-12.88
2015-16.58-3.3615.06